Abstract
Successful vaccination strategies offer the potential for lifelong immunity against infectious diseases and cancer. There has been increased attention regarding the limited translation of some preclinical findings generated using specific pathogen-free (SPF) laboratory mice to humans. One potential reason for the difference between preclinical and clinical findings lies in maturation status of the immune system at the time of challenge. In this study, we used a “dirty” mouse model, where SPF laboratory mice were cohoused (CoH) with pet store mice to permit microbe transfer and immune system maturation, to investigate the priming of a naive T cell response after vaccination with a peptide subunit mixed with polyinosinic-polycytidylic acid and agonistic antiCD40 mAb. Although this vaccination platform induced robust antitumor immunity in SPF mice, it failed to do so in microbially experienced CoH mice. Subsequent investigation revealed that despite similar numbers of Ag-specific naive CD4 and CD8 T cell precursors, the expansion, differentiation, and recall responses of these CD4 and CD8 T cell populations in CoH mice were significantly reduced compared with SPF mice after vaccination. Evaluation of the dendritic cell compartment revealed reduced IL-27p28 expression by XCR1+ dendritic cells from CoH mice after vaccination, correlating with reduced T cell expansion. Importantly, administration of recombinant IL-27:EBI3 complex to CoH mice shortly after vaccination significantly boosted Ag-specific CD8 and CD4 T cell expansion, further implicating the defect to be T cell extrinsic. Collectively, our data show the potential limitation of exclusive use of SPF mice when testing vaccine efficacy.
Original language | English (US) |
---|---|
Pages (from-to) | 2149-2159 |
Number of pages | 11 |
Journal | Journal of Immunology |
Volume | 209 |
Issue number | 11 |
DOIs | |
State | Published - Dec 1 2022 |
Bibliographical note
Funding Information:Award I01BX001324 (to T.S.G.). T.S.G. is the recipient of a Research Career Scientist award (IK6BX006192) from the U.S. Department of Veterans Affairs.
Funding Information:
This work was supported by the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases Grants AI155468 (to S.E.H.) and T32AI007313 (to F.V.S.); NIH, National Institute of General Medical Sciences Grants GM115462 and GM140881 (to T.S.G.); and a U.S. Department of Veterans Affairs Merit Review
Publisher Copyright:
Copyright © 2022 by The American Association of Immunologists, Inc.
PubMed: MeSH publication types
- Journal Article
- Research Support, N.I.H., Extramural
- Research Support, U.S. Gov't, Non-P.H.S.